Staying on hormone therapy for early breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well patients take their hormone-lowering pills (aromatase inhibitors, with or without abemaciclib) for early-stage breast cancer. It aims to understand adherence patterns and help improve support for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female
- You have early-stage, hormone receptor-positive, HER2-negative breast cancer
- You are currently taking an aromatase inhibitor (letrozole, anastrozole, or exemestane), with or without abemaciclib, for no more than 18 months
- You are being treated at the Institute of Oncology Ljubljana
- You have mandatory health insurance in Slovenia
- You understand Slovenian and agree to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well patients take ribociclib (a cancer-fighting drug) combined with hormone therapy for early-stage breast cancer, and monitors for any side effects. The goal is to understand real-world use and help patients stay on treatment safely.
This study helps women with early-stage hormone-receptor-positive breast cancer take their oral medication (abemaciclib) consistently and correctly. The goal is to improve how well women stick with this treatment by offering support and education.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.